Want to see SE:ATORX full AI Analyst Report?
ATORX Stock Chart & Stats
kr0.34
-kr0.03(-72.12%)
At close: 4:00 PM EST
kr0.34
-kr0.03(-72.12%)
Day’s Range― - ―
52-Week Rangekr0.16 - kr1.69
Previous CloseN/A
Volume998.30M
Average Volume (3M)1.75M
Market Cap
kr101.34M
Enterprise Valuekr5.52M
Total Cash (Recent Filing)kr32.98M
Total Debt (Recent Filing)kr32.38M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding534,516,970
10 Day Avg. Volume1,169,449
30 Day Avg. Volume1,745,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Partnering-focused Business ModelA partnering/licensing model is capital-efficient for clinical-stage biotech: it allows the company to leverage larger partners for late-stage development and commercialization, unlocking milestone and royalty streams without needing a full commercial infrastructure.
Balance-sheet ImprovementMaterial reduction in leverage and a return to positive equity enhance financial flexibility. Lower debt burden reduces refinancing risk and gives more runway to progress clinical programs or negotiate partnerships before needing dilutive financing.
Clinical-stage Immuno-oncology FocusA pipeline centered on antibody immunotherapies addresses persistent unmet needs in oncology. Clinical-stage assets in these mechanisms remain attractive for partners and can generate milestone-driven funding and strategic collaborations over the medium term.
Bears Say
High Cash BurnSustained negative operating and free cash flow of this magnitude creates an enduring funding requirement. Continued cash burn increases reliance on partnerships, milestone receipts or equity markets, raising dilution and execution risk if clinical progress slows.
Very Limited And Declining RevenueMinimal and falling revenue underscores lack of recurring commercial income. This makes operational financing lumpy and tied to one-off deals or milestones, reducing predictability of funding for R&D and limiting the company’s ability to steadily scale operations.
Persistent Operating LossesChronic operating losses indicate the business has not yet reached breakeven potential. Continued negative margins pressure equity and may necessitate frequent capital raises, which can dilute shareholders and constrain long-term strategic choices absent successful partnering or clinical readouts.
Alligator Bioscience AB News
ATORX FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest stock price was kr0.16 and its highest was kr1.69 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr101.34M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is Aug 27, 2026 which is in 36 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on May 05, 2026. The company reported kr0.003 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 534,516,970 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of kr0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.469%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in SE:ATORX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ) is a research-intensive biotechnology company based in Lund, Sweden, focused on developing innovative antibody-based treatments for cancer. The company leverages several proprietary technology platforms to drive its drug development. These include ALLIGATOR-GOLD and ALLIGATOR-FAB, an extensive human antibody library boasting roughly 60 billion distinct antibody fragments; FIND, a molecular evolution technique used for optimizing antibodies and other proteins; and RUBY, a specialized format for creating bispecific antibodies. Alligator Bioscience's pipeline features several promising candidates. In the clinical stage, Mitazalimab, an immunostimulatory CD40 antibody, has successfully completed Phase I trials for metastatic cancer. Also undergoing Phase I clinical evaluation is ATOR-1017, another immunostimulatory antibody designed to bind to the 4-1BB receptor on tumor-specific T cells. For its preclinical efforts, the company is advancing ALG.APV-527, a bispecific antibody targeting both 4-1BB and 5T4 for cancer therapy. Additionally, Alligator Bioscience holds an interest in the Biosynergy (AC101) project, which is currently in Phase I. To bolster its research and development capabilities, Alligator Bioscience has formed multiple strategic collaborations. It has a co-development partnership with Aptevo Therapeutics Inc. for ALG.APV-527, and a research alliance with MacroGenics, Inc. to create novel immunotherapies. Further collaborations include a joint research agreement with BioArctic AB (publ) to utilize proprietary antibody generation technologies for new product candidates, and a research and license agreement with Orion Corporation aimed at discovering and developing new bispecific antibody cancer therapeutics. The company was established in 2000.
Technical Analysis
Alzinova AB
―
Nanologica AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
NextCell Pharma AB
―